We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Prevalence and Impact of Lupus Anticoagulant in Patients Receiving Extracorporeal Membrane Oxygenation.
- Authors
Kornfehl, Andrea; Brock, Roman; Staudinger, Thomas; Schellongowski, Peter; Nagler, Bernhard; Hermann, Alexander; Robak, Oliver; Schwameis, Michael; Quehenberger, Peter; Buchtele, Nina
- Abstract
Background: Monitoring of blood coagulation is essential in ECMO patients. We investigated the prevalence of lupus anticoagulant (LA) and its association with coagulation testing and hemostaseologic complications in patients treated with ECMO. Methods: This is a retrospective analysis including adult patients who received ECMO at a medical intensive care unit at the Medical University of Vienna. The primary outcome was the prevalence of LA. Secondary outcomes included conditions associated with LA positivity, rates of bleeding and thromboembolic events, as well as the proportions of aPTT and antiXa measurements within the target range. Results: Between 2013 and 2021 193 patients received ECMO, in 62 (32%) of whom LA diagnostics were performed. Twenty-two (35%) patients tested positive. LA positive patients had more frequently received VV ECMO (77.3% vs 34.3%; p = 0.002), were more frequently diagnosed with viral respiratory infections (SARS-CoV2: 45.5% vs 20%; p = 0.041, influenza virus: 22.7% vs 0%; p = 0.003), had a longer ECMO treatment duration (25 vs 10 days; p = 0.011) and a longer ICU stay (48 vs 25 days; p = 0.022), but similar rates of bleeding and thromboembolic events.
- Subjects
MEDIZINISCHE Universitat Wien; EXTRACORPOREAL membrane oxygenation; STUDENT health services; BLOOD coagulation; INTENSIVE care units; ANTICOAGULANTS
- Publication
Clinical & Applied Thrombosis/Hemostasis, 2023, Vol 29, p1
- ISSN
1076-0296
- Publication type
Article
- DOI
10.1177/10760296231207062